TOP TEN BY ONCOALERT

BREAST CANCER



LBA1000

TRASTUZUMAB DERUXTECAN (T-DXD) VS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (TPC) IN HR+, HER2-LOW OR HER2-ULTRALOW METASTATIC BREAST CANCER (MBC) WITH PRIOR ENDOCRINE THERAPY: PRIMARY RESULTS FROM DESTINY-BREASTO6

1005

ENFORTUMAB VEDOTIN (EV) IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) AND HR+/HER2-BREAST CANCER (BC) COHORTS OF EV-202.

1009

DESTINY-BREASTO7: DOSE-EXPANSION INTERIM ANALYSIS OF T-DXD MONOTHERAPY AND T-DXD + PERTUZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED HER2+ MBC.

LBA1001

ABEMACICLIB PLUS FULVESTRANT VS FULVESTRANT ALONE FOR HR+, HER2- ADVANCED BREAST CANCER FOLLOWING PROGRESSION ON A PRIOR CDK4/6 INHIBITOR PLUS ENDOCRINE THERAPY: PRIMARY OUTCOME OF **POSTMONARCH TRIAL**

LBA1002

PALBOCICLIB PLUS EXEMESTANE WITH GNRH AGONIST VS CAPECITABINE IN PREMENOPAUSAL PATIENTS WITH HR+/HER2- METASTATIC BREAST CANCER: UPDATED SURVIVAL RESULTS OF PHASE 2 STUDY YOUNG-PEARL

LBA1004

SACI-IO HR+: A RANDOMIZED PHASE II TRIAL OF SACITUZUMAB GOVITECAN WITH OR WITHOUT PEMBROLIZUMAB IN PATIENTS WITH METASTATIC HR+/HER2- BREAST CANCER.

LBA500

A-BRAVE: PHASE III RANDOMIZED TRIAL WITH AVELUMAB IN EARLY TNBC WITH RESIDUAL DISEASE AFTER NEOADJ CHEMOTHERAPY OR AT HIGH RISK AFTER 1RY SURGERY AND ADJ. CHEMOTHERAPY.

LBA501

RATES OF PATHOLOGIC COMPLETE RESPONSE (PCR) AFTER DATOPOTAMAB DERUXTECAN (DATO) PLUS DURVALUMAB IN THE NEOADJUVANT SETTING: RESULTS FROM I-SPY2.2

1025

TRASTUZUMAB DERUXTECAN (T-DXD) VS TRASTUZUMAB EMTANSINE (T-DM1) IN PATIENTS W/ HER2+ METASTATIC BREAST CANCER (MBC): UPDATED SURVIVAL RESULTS OF **DESTINY-BREASTO3**.

1012

ON-TREATMENT (TX) DYNAMIC CIRCULATING TUMOR DNA CHANGES (ΔCTDNA) ASSOCIATED WITH PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) OF PATIENTS (PTS) WITH HR+/HER2- ADVANCED BREAST CANCER (ABC) IN MONALEESA-3

Leads



Dr Agostinetto Med Onc



Dr Bonzano Rad Onc



Clin Onc

Faculty

Dr Hamilton

Med Onc

Dr Graff

Med Onc



Med Onc



Dr Rugo

Med Onc

Dr Tolaney

Med Onc



Dr Lambertini



Ms Cowden Advocate Med Onc